By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Takeda Pharmaceutical Company will use a biomarker assay developed by Zinfandel Pharmaceuticals as part of a clinical trial investigating the utility of Takeda's drug Actos in Alzheimer's disease, the companies said this week.

Under the terms of the agreement, Takeda has taken an exclusive, worldwide license for the use of Zinfandel's TOMM40 assay as a biomarker for the risk of Alzheimer's disease in high-risk older adults with normal cognition.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.